Mesothelioma | Mesothelioma

The 2005 amounts relate primarily to a $2.0 million license fee paid, through the issuance of Company stock, to Sanofi-Aventis for rights to commercialize products using interleukin-13 (IL-13), a compound that contributes to the transformation of white blood cells into specialized immune cells called dendritic cells.

The full amount was written off in accordance with the Company's policy as there is not a program which uses IL-13 that has reached Phase III development.

The 2004 amounts relate primarily to licenses to certain antibodies from Medarex, which the Company wrote off in accordance with its established policies as it was no longer pursuing development of those antibodies.

Selling and marketing expenses, which include business development costs, trade conferences and the Company's pre-launch activities for its lead product candidate Junovan(TM), were $0.3 million and $1.3 million, respectively, for the quarter and year ended December 31, 2005, compared to $0.3 million and $1.2 million for the same periods in 2004.

The increase in the amounts for 2005 compared to 2004 is associated with preliminary pre-marketing activities for Junovan.

General and administrative (...

The machine three-dimensionally locates the tumor and delivers a highly concentrated blast of radiation.

"What happens is you save the healthy lung and at the same time, kill the small tumor,” Radiation Oncologist Dr.

Anil Sharma said.

There are only a few dozen of these machines in the world.

One of them is right here in Orlando at M.D.

Anderson Cancer Center.

Dr.

Robert Nagourney is treating Virginia Filipan at the Long Beach Memorial Medical Center in California.

Instead of giving the same kind of chemotherapy to a broad range of patients, the staff developed a unique program to examine a patient's tissue sample and individually tailor treatment.

"We have labs where we can isolate cancer cells and measure the effect of drugs better than virtually anyone else," Dr.

Nagourney said.

They basically biopsy the patient, remove a piece of the tumor and expose it to all kinds of drug combinations in a test tube, and find the ones that work best at killing their cancer.

In Virginia's case, it's a pill she takes once a day.

"I walked in this hospital in a walker, the day of my biopsy, because I couldn't walk by myself,” Virginia said.

“And now I have no problems walking." That's a look at Your Health, Nancy Gay, Central Florida News 13.

Print Archive  ...